Expertise and resources to facilitate
Read or watch to learn more
Preclinical characterization of oncology nanomedicines
Expediting nanomedicine development
Protocols

Nanotechnology Characterization Lab

Eliminating suffering and death from cancer requires an unprecedented collaborative effort that leverages resources from government, industry, and academia. Working in concert with the National Institute of Standards and Technology (NIST) and the U.S. Food and Drug Administration (FDA), the National Cancer Institute (NCI) established the Nanotechnology Characterization Laboratory to perform preclinical efficacy and toxicity testing of nanoparticles.

The NCL serves as a national resource and knowledge base for all cancer researchers to facilitate the regulatory review of nanotechnologies intended for cancer therapies and diagnostics. By providing the critical infrastructure and characterization services to nanomaterial providers, the NCL accelerates the transition of basic nanoscale particles and devices into clinical applications, thereby reducing suffering and death from cancer.

There are multiple ways the NCL can help nanotech researchers and developers advance their technology, including characterization, reformulation, optimization, lead selection, method development, and more.

Learn about how to collaborate with the NCL.

News & Updates

The NCL is proud to announce the appointment of Drs.

By popular request, the NCL will revert back to quarterly deadlines for the NCL’s Assay Cascade characterization service.

The National Cancer Institute’s Nanodelivery Systems and Devices Branch has compiled the following list of funding opportunities and translational resources that may be of...

Meet Us @

Laboratory co-Director and Head of NCL’s Immunology Section, Dr. Marina Dobrovolskaia, will be co-chairing a session with Dr.

NCL Sr. Scientist Dr. Rachael Crist will be representing the NCL at the annual BIO International Convention. The next meeting is being held in San Diego, CA, June 8-11.